Literature DB >> 22264944

Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

Sara Brandi Bloch1, Michael Larsen, Inger Christine Munch.   

Abstract

PURPOSE: To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark from years 2000 to 2010 in the age group at risk of AMD aged 50 years and older.
DESIGN: Population-based observational registry study.
METHODS: settings: Membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. study population: A total of 11 848 incident cases of legal blindness from a population of citizens aged ≥50 years numbering 1.71 million in 2000 and 1.87 million in 2010 with free access to a single-payer public health care system. main outcome measures: Incidence rates of legal blindness from AMD from 2000 to 2010.
RESULTS: The incidence rate of legal blindness attributable to AMD in citizens aged ≥50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI(95)]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006. The incidence of legal blindness from causes other than AMD decreased by 33% (CI(95): 21%-44%, P < .0001), most of the reduction occurring between 2000 and 2006.
CONCLUSION: From 2000 to 2010 the incidence of legal blindness from AMD fell to half the baseline incidence. The bulk of the reduction occurred after the introduction of intravitreally injected inhibitors of vascular endothelial growth factor in 2006.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264944     DOI: 10.1016/j.ajo.2011.10.016

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  82 in total

1.  Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration.

Authors:  Sibel Doguizi; Sengul Ozdek; Selcen Yuksel
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.

Authors:  Julie Jacob; Heidi Brié; Anita Leys; Laurent Levecq; Filip Mergaerts; Kris Denhaerynck; Stefaan Vancayzeele; Eline Van Craeyveld; Ivo Abraham; Karen MacDonald
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

3.  Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland.

Authors:  S Borooah; V S Jeganathan; A-M Ambrecht; D Oladiwura; M Gavin; B Dhillon; P Cackett
Journal:  Eye (Lond)       Date:  2015-06-05       Impact factor: 3.775

4.  [Requirements for low vision magnification aids in age-related macular degeneration: Data from the Tübingen low vision clinic (comparison of 2007-2011 with 1999-2005)].

Authors:  E K Altpeter; N X Nguyen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

5.  The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration.

Authors:  Frank A Sloan; Brian W Hanrahan
Journal:  JAMA Ophthalmol       Date:  2014-04-01       Impact factor: 7.389

6.  Biotherapeutics and immunogenicity: ophthalmic perspective.

Authors:  Ashish Sharma; Nilesh Kumar; Baruch D Kuppermann; Francesco Bandello; Anat Loewenstein
Journal:  Eye (Lond)       Date:  2019-04-09       Impact factor: 3.775

Review 7.  Age-related macular degeneration.

Authors:  Monika Fleckenstein; Tiarnán D L Keenan; Robyn H Guymer; Usha Chakravarthy; Steffen Schmitz-Valckenberg; Caroline C Klaver; Wai T Wong; Emily Y Chew
Journal:  Nat Rev Dis Primers       Date:  2021-05-06       Impact factor: 52.329

8.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

9.  Rate of vision loss in neovascular age-related macular degeneration explored.

Authors:  Juan P Real; Gladys E Granero; Mariana O De Santis; Claudio P Juarez; Santiago D Palma; Simon P Kelly; José D Luna
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-11       Impact factor: 3.117

10.  Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.

Authors:  Arseniy P Yashkin; Paul Hahn; Frank A Sloan
Journal:  Ophthalmology       Date:  2016-08-11       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.